NDAORALTABLETPriority Review
Approved
Jan 2023
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
JAYPIRCA (pirtobrutinib) by Eli Lilly and Company is bruton's tyrosine kinase inhibitors [moa]. First approved in 2023.
Drug data last refreshed 8h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
JAYPIRCA (pirtobrutinib) is an oral Bruton's Tyrosine Kinase (BTK) inhibitor approved in January 2023 for hematologic malignancies, particularly chronic lymphocytic leukemia and other B-cell lymphomas. It works by selectively inhibiting BTK, a key enzyme in B-cell receptor signaling pathways critical to cancer cell survival and proliferation.
$0.049BPart D
Peak15.1 years to LOEPeak-stage oral oncology product with strong patent protection through 2041; expect stable, specialized commercial infrastructure focused on hematology-oncology channels.
Mechanism of Action
Bruton's Tyrosine Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)
Started Jun 2026
25 enrolled
Waldenstrom Macroglobulinemia
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
Started Jun 2026
620 enrolled
B-cell LymphomaChronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Started Apr 2026
306 enrolled
CLL / SLLCLL (Chronic Lymphocytic Leukemia)CLL, Refractory+5 more
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Started Mar 2026
150 enrolled
Chronic Lymphocytic LeukemiaLymphoma, Small Lymphocytic
PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma
Started Feb 2026
56 enrolled
Mantle Cell Lymphoma
Worked on JAYPIRCA at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.